Are Elderly Patients With Clinically Localized Prostate Cancer Overtreated? Exploring Heterogeneity in Survival Effects.

Are Elderly Patients With Clinically Localized Prostate Cancer Overtreated? Exploring Heterogeneity in Survival Effects.
复制标题

DOI:
10.1097/mlr.0000000000000260
复制
发表时间:
2015-01
期刊:
影响因子:
3
通讯作者:
Gore JL
Gore JL
中科院分区:
医学3区
文献类型:
--
作者:
Basu A;Gore JL

文献摘要

被引文献

相似文献

Clinical trial evidence shows minimal survival gains and higher complication rates from prostatectomy (RP) versus watchful waiting (WW) for elderly men with localized prostate cancer. It is believed that these patients are overtreated. The current analyses aim to explore patient-level heterogeneity in survival effects, examine matching of patients to treatments in practice, and identify patient characteristics driving heterogeneous effects, in order to present more comprehensive evidence about the concerns of overtreatment. 11-year all-cause and prostate cancer-specific survival among SEER-Medicare patient diagnosed during 1996 to 2002 were analyzed using local instrumental variable approaches. 8,462 (77%) out of 11,036 patients received RP. The average effects of RP over WW on 11-year overall and cancer-specific survival were 1.1 months (95%CI: −25, 28; p = 0.94) and 1.7 months (95%CI: −25, 29; p = 0.90) respectively; effects did not differ significantly according to age, race, grade and stage. Fewer than 1% of patients had significant cancer-specific survival benefit from RP at the 10% level; 6% were expected to gain over 15 months from RP. However, patients with larger expected survival gains from RP were much more likely to receive RP in practice. Such positive self-selection was driven by prostate cancer-specific survival than overall survival. Several comorbidities may play a critical role in predicting who could benefit from RP. Our analyses corroborate concerns about prostate cancer overtreatment. A small fraction of screen-detected prostate cancer patients derive survival benefits from RP. Prediction tools should account for patient comorbidities to accurately predict survival benefits of RP over WW.